Múltiples sesiones de hipertermia con fluidos magnéticos: un requisito para la apoptosis en células de cáncer de...

Magnetic fluid hyperthermia (MFH) is emerging as a promising cancer therapeutic modality due to its minimal side effects and targeted approach. This study presents the synthesis and characterization of temperature-sensitive biocompatible magnetic fluid (MF) containing citric acid-coated Mn0.9Zn0.1Fe2O4 nanoparticles, along with in vitro investigations on the prostate cancer cells LNCaP, to demonstrate the potential of these nanoparticles as a hyperthermic agent for MFH. The biocompatibility of MF was assessed using the MTT assay, which demonstrated no cytotoxic effects at concentrations up to 3 mg/mL. Furthermore, rapid internalization of nanoparticles into LNCaP prostate cancer cells was observed within 10 minutes, as determined by a Prussian blue assay and quantified by Inductively Coupled Plasma Mass Spectrometry. Upon exposure to an alternating magnetic field of 10 kA/m and 332 kHz frequency, the nanoparticles achieved the therapeutic temperature of 42 °C within 27 minutes, while sustaining a hyperthermic range of 42 to 45 °C for one hour. Notably, three MFH treatment sessions were identified as requisite for the elimination of LNCaP cells. Apoptosis was identified using Hoechst-Propidium iodide (PI) staining and further quantified by Annexin-V/PI flow cytometry. These findings underscore the potential of CA-coated Mn-Zn ferrite nanoparticles as effective biocompatible agents for MFH-based cancer therapy, warranting further detailed investigations to elucidate their therapeutic efficacy.